Silence Therapeutics plc (SLN) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Sell.
The consensus price target is $57.00 (low: $49.00, high: $67.00), representing an upside of 683% from the current price $7.28.
Analysts estimate Earnings Per Share (EPS) of $-0.72 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.98 vs est $-0.72 (missed -35.8%). 2025: actual $-1.89 vs est $-0.91 (missed -108.5%). Analyst accuracy: 61%.
SLN Stock — 12-Month Price Forecast
$57.00
▲ +682.97% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Silence Therapeutics plc, the average price target is $57.00, with a high forecast of $67.00, and a low forecast of $49.00.
The average price target represents a +682.97% change from the last price of $7.28.
Highest Price Target
$67.00
Average Price Target
$57.00
Lowest Price Target
$49.00
SLN Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Silence Therapeutics plc in the past 3 months
EPS Estimates — SLN
61%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.98
vs Est –$0.72
▼ 26.4% off
2025
Actual –$1.89
vs Est –$0.91
▼ 52.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — SLN
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.043B
vs Est $0.025B
▲ 42.1% off
2025
Actual $0.001B
vs Est $0.008B
▼ 1,308.8% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
